IP Library › Granted Patent US 12,473,552
Granted Patent B2
US 12,473,552 · App. 19/092,326 · Granted Nov 18, 2025

Composition for regulating production of interfering ribonucleic acid

Inventor: Bradley G. Thompson (Calgary, CA)
Assignee: Wyvern Pharmaceuticals Inc.
C12N15/1137C12N15/113C12N15/86C12Y114/16002C12N2310/141C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,473,552
App. No.
19/092,326
Granted
Nov 18, 2025
Kind
B2
Abstract

The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a protein that participates in one or more intracellular processes.

Claims (5)

1 . A composition that comprises a recombinant plasmid (RP) comprising SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7, wherein: SEQ ID NO: 5 comprises SEQ ID NO: 2, SEQ ID NO: 6 comprises SEQ ID NO: 3, and SEQ ID NO: 7 comprises SEQ ID NO: 4.

2 . The composition of claim 1 , wherein the RP is encapsulated in a protein coat, a lipid vesicle, or any combination thereof.

3 . The composition of claim 1 , wherein SEQ ID NO: 5 comprises SEQ ID NO: 2.

4 . The composition of claim 1 , wherein SEQ ID NO: 6 comprises SEQ ID NO: 3.

5 . The composition of claim 1 , wherein SEQID NO: 7 comprises SEQ ID NO: 4.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2025
From: THOMPSON, BRADLEY G.
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 071987/0576 →
Continuity (2)
Continuation 18518014 · Nov 22, 2023
Related Publication 20250223598A1 · Jul 10, 2025
References Cited (31)
US 1162102A · Rager · 1915 [cited by applicant]
US 11085055B2 · Mallol et al. · 2021 [cited by applicant]
US 11530423B1 · Thompson · 2022 [cited by applicant]
US 11873505B2 · Thompson · 2024 [cited by applicant]
US 12018274B2 · Thompson · 2024 [cited by applicant]
US 12134770B1 · Thompson · 2024 [cited by applicant]
US 20240026377A1 · Thompson · 2024 [cited by applicant]
CA 2721333A1 · 2009 [cited by applicant]
O'Brien at al., “Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation” Aug. 3, 2018, Frontiers in Endocrinology, 9:402, p. 1-12. (Year: 2018). [cited by examiner]
Zhang et al., “The Risks of miRNA Therapeutics: In a Drug Target Perspective”, Drug Design, Development and Therapy, Published Feb. 22, 2021, pp. 721-733. (Year: 2021). [cited by examiner]
Van den Berg et al., “Design of Effective Primary MicroRNA Mimics With Different Basal Stem Conformations”, Molecular Therapy, Nucleic Acids, vol. 5, 2016. (Year: 2016). [cited by examiner]
Denzler R et al., “Impact of MicroRNA Levels, Target-Site Complementarity, and Cooperativity on Competing Endogenous RNA-Regulated Gene Expression”; Mol Cell. Nov. 3, 2016;64:565-579). (Year: 2016). [cited by examiner]
GenBank FLT3 Sequence (2024). [cited by applicant]
Gorski et al. “RNA-based recognition and targeting: sowing the seeds of specificity.” Nature Reviews Molecular Cell Biology 18.4 (2017): 215-228. [cited by applicant]
Bottoni et al. “Targeting BTK through microRNA in chronic lymphocytic leukemia.” Blood, The Journal of the American Society of Hematology 128.26 (2016): 3101-3112. [cited by applicant]
Christensen et al. “Recombinant adeno-associated virus-mediated microRNA delivery into the postnatal mouse brain reveals a role for miR-134 in dendritogenesis in vivo.” Frontiers in neural circuits 3 (2010): 848. [cited by applicant]
Bofill-De Ros et al. “Guidelines for the optimal design of miRNA-based shRNAs.” Methods 103 (2016): 157-166. [cited by applicant]
NCBI Nucleotide Sequence for PARP, search performed Dec. 26, 2024 (2024). [cited by applicant]
NCBI Nucleotide Sequence ALK Receptor, search performed Dec. 26, 2024 (2023). [cited by applicant]
Tritschler et al. “Concepts and limitations for learning developmental trajectories from single cell genomics.” Development 146.12 (2019): dev170506. [cited by applicant]
Ahmadzadeh et al. “BRAF mutation in hairy cell leukemia.” Oncology reviews 8.2 (2014): 253. [cited by applicant]
Patton et al. “Biogenesis, delivery, and function of extracellular RNA.” Journal of extracellular vesicles 4.1 (2015): 27494. [cited by applicant]
Clark et al. “Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies.” Oncotarget 11.44 (2020): 4016. [cited by applicant]
Wang et al. “Adeno-associated virus vector as a platform for gene therapy delivery.” Nature reviews Drug discovery 18.5 (2019): 358-378. [cited by applicant]
Kondratov et al. “Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells.” Molecular Therapy 25.12 (2017): 2661-2675. [cited by applicant]
Nature (2010. Gene Expression. Scitable. Available online at Nature.com) <https://www.nature.com/scitable/topicpage/gene-expression-14121669> (2010). [cited by applicant]
Brutons Tyrosine Kinase Genbank Sequence (2023). [cited by applicant]
GenBank EGFR Sequence (2023). [cited by applicant]
GenBank EGF Sequence (2023). [cited by applicant]
NCBI search results for SEQ ID No. 5 (2024). [cited by applicant]
NCBI Nucleotide Sequence ALK Lingand, search performed Dec. 26, 2024 (2023). [cited by applicant]